NCT06370780

Exploring, Predicting, and Intervening on Long-term Viral Suppression Electronically

Name: Clinical Trial NCT06370780
Creator: University of California, Los Angeles
Keywords: HIV Infections, EPI LOVE, other, clinical trial, United States of America

University of California, Los Angeles·ClinicalTrials.gov·otherRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: HIV Infections
Drug/Device/Intervention: EPI LOVE
Study type: Interventional
Intervention type: other

Sponsor & location

Primary sponsor: University of California, Los Angeles
Location: Los Angeles, United States of America

Timeline & enrollment

Phase: N/A
Start date: Feb 09, 2024
End date: Apr 30, 2025
Enrollment: 1000 participants

Primary outcome

Incidence of HIV Viral Suppression,Level of Adherence to HIV medication,Level of Adherence based on HIV appointments

Summary

Despite the widespread availability of effective antiretroviral therapy (ART) in the United States, there remains significant numbers of people living with HIV (PLWH) who fail to achieve and or maintain viral suppression (VS). Disparities persist with the lowest levels of VS among Black individuals, people who use drugs, youth ages 18-24 and people residing in rural areas. Investigators will examine the syndemics underlying these outcomes including substance use, mental health, and barriers to HIV care including racial discrimination, stigma and rural isolation.

ICD-10 classifications

HIV disease resulting in other viral infectionsHIV disease resulting in other bacterial infectionsHIV disease resulting in multiple infectionsAcute HIV infection syndromeHIV disease resulting in other infectious and parasitic diseases

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06370780
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06370780 through Pure Global AI's free database. This phase not specified trial is sponsored by University of California, Los Angeles and is currently Recruiting. The study focuses on HIV Infections. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.